 VYNE Therapeutics Inc NASDAQ: VYNE announced preclinical data for VYN201, its pan-bromodomain and extra-terminal BET inhibitor. The data showed that VYN201 significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an ex vivo human tissue study. 